Cargando…
Platelet-derived growth factor in glioblastoma—driver or biomarker?
TP53: The platelet-derived growth factor (PDGF) family of mitogens exerts vital functions during embryonal development, e.g. in the central nervous system, where PDGF drives the proliferation of oligodendrocyte precursors. PDGF and PDGF receptors are co-expressed in human glioblastoma (GBM). Whether...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248069/ https://www.ncbi.nlm.nih.gov/pubmed/25342206 http://dx.doi.org/10.3109/03009734.2014.970304 |
_version_ | 1782346750242062336 |
---|---|
author | Westermark, Bengt |
author_facet | Westermark, Bengt |
author_sort | Westermark, Bengt |
collection | PubMed |
description | TP53: The platelet-derived growth factor (PDGF) family of mitogens exerts vital functions during embryonal development, e.g. in the central nervous system, where PDGF drives the proliferation of oligodendrocyte precursors. PDGF and PDGF receptors are co-expressed in human glioblastoma (GBM). Whether an aberrant activation of the PDGF receptor pathway is a driving force in glioma development has remained an open question. In experimental animals, overexpression of PDGF has convincingly been shown to induce tumors, both in wild-type animals (marmoset, rat, mouse) and in mice with targeted deletions of suppressor genes, e.g. Tp53 or Ink4A. Targeting the PDGF receptor in tumor-bearing mice leads to growth inhibition and reversion of the transformed phenotype. Findings of PDGF receptor amplification or mutations in human GBM are strong indicators of a causative role of the PDGF receptor pathway. However, clinical trials using PDGF receptor antagonists have been disappointing. In conclusion, a PDGF receptor profile may be a biomarker for a subgroup of GBM originating from a PDGF receptor-responsive cell. Although compelling experimental and clinical evidence supports the notion that the PDGF receptor pathway is a driver in GBM, formal proof is still missing. |
format | Online Article Text |
id | pubmed-4248069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-42480692014-12-12 Platelet-derived growth factor in glioblastoma—driver or biomarker? Westermark, Bengt Ups J Med Sci Review Article TP53: The platelet-derived growth factor (PDGF) family of mitogens exerts vital functions during embryonal development, e.g. in the central nervous system, where PDGF drives the proliferation of oligodendrocyte precursors. PDGF and PDGF receptors are co-expressed in human glioblastoma (GBM). Whether an aberrant activation of the PDGF receptor pathway is a driving force in glioma development has remained an open question. In experimental animals, overexpression of PDGF has convincingly been shown to induce tumors, both in wild-type animals (marmoset, rat, mouse) and in mice with targeted deletions of suppressor genes, e.g. Tp53 or Ink4A. Targeting the PDGF receptor in tumor-bearing mice leads to growth inhibition and reversion of the transformed phenotype. Findings of PDGF receptor amplification or mutations in human GBM are strong indicators of a causative role of the PDGF receptor pathway. However, clinical trials using PDGF receptor antagonists have been disappointing. In conclusion, a PDGF receptor profile may be a biomarker for a subgroup of GBM originating from a PDGF receptor-responsive cell. Although compelling experimental and clinical evidence supports the notion that the PDGF receptor pathway is a driver in GBM, formal proof is still missing. Informa Healthcare 2014-11 2014-11-04 /pmc/articles/PMC4248069/ /pubmed/25342206 http://dx.doi.org/10.3109/03009734.2014.970304 Text en © Informa Healthcare http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the CC-BY-NC-ND 3.0 License which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is credited. |
spellingShingle | Review Article Westermark, Bengt Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title | Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title_full | Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title_fullStr | Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title_full_unstemmed | Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title_short | Platelet-derived growth factor in glioblastoma—driver or biomarker? |
title_sort | platelet-derived growth factor in glioblastoma—driver or biomarker? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248069/ https://www.ncbi.nlm.nih.gov/pubmed/25342206 http://dx.doi.org/10.3109/03009734.2014.970304 |
work_keys_str_mv | AT westermarkbengt plateletderivedgrowthfactoringlioblastomadriverorbiomarker |